Riik: Malaisia
keel: inglise
Allikas: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)
CLOSTRIDIUM BOTULINUM TOXIN TYPE A
Allergan Malaysia Sdn Bhd
CLOSTRIDIUM BOTULINUM TOXIN TYPE A
1Pieces Pieces; 1 Pieces Pieces
ALLERGAN PHARMACEUTICALS IRELAND
Not Applicable Lugege kogu dokumenti
BOTOX ® (Botulinum Toxin Type A) Purified Neurotoxin Complex P RESENTATION A sterile white vacuum dried powder in a clear glass vial, for use in a single patient. One unit corresponds to the median lethal dose (LD 50) when reconstituted BOTOX ® is injected intraperitoneally into mice under defined conditions). Each vial of BOTOX® 50 Units contains 50 Units of Clostridium botulinum type A neurotoxin complex 900kD, 0.25 mg of human albumin and 0.45 mg of sodium chloride in a sterile, vacuum -dried form without a preservative. Each vial of BOTOX® 100 Units contains 100 Units of Clostridium botulinum type A neurotoxin complex 900kD, 0. 5 mg of human albumin and 0.9 mg of sodium chloride in a sterile, vacuum -dried form without a preservative. Each vial of BOTOX® 200 Units contains 200 Units of Clostridium botulinum type A neurotoxin complex 900kD, 1.0 mg of human albumin and 1.8 mg of sodium chloride in a sterile, vacuum-dried form without a preservative. USES BOTOX ® (botulinum toxin type A) purified neurotoxin complex is indicated for the following therapeutic indications : • BOTOX ® is indicated for the treatment of blepharospasm associated with dystonia, including benign essential blepharospasm, hemifacial spasm and VIIth nerve disorders in patients 12 years or older. • BOTOX ® is indicated for the correction of strabismus in patients 12 years of age or older. • BOTOX ® is indicated for the treatment of spasmodic torticollis (cervical dystonia) in adults. • BOTOX ® is indicated for the treatment of dynamic equinus foot deformity due to spasticity in paediatric cerebral palsy patients, two years of age and older. • BOTOX ® is indicated in the manageme nt of focal spasticity: o including wrist and hand disability due to upper limb spasticity associated with stroke in adults. o Including ankle and foot disability due to lower limb spasticity associated with stroke in adult s. Distant Spread of Toxin Effect Postmarketing safety data from BOTOX and other approved botulinum toxins suggest that bo Lugege kogu dokumenti